Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4023110 | 0.86 | HSD17B10 (0.42) | HSD17B10ACE2 | |
| SCHEMBL4024810 | 0.84 | HSD17B10 (0.41) | HSD17B10 | |
| SCHEMBL5574053 | 0.82 | HSD17B10 (0.47) | HSD17B10ACE2 | |
| SCHEMBL5241070 | 0.81 | — | — | |
| SCHEMBL10975227 | 0.78 | HSD17B10 (0.44) | HSD17B10ALOX15GAA | |
| SCHEMBL2087117 | 0.78 | HSD17B10 (0.48) | HSD17B10CYP2C19 | |
| SCHEMBL21751013 | 0.78 | HSD17B10 (0.44) | HSD17B10ALOX15GAA | |
| SCHEMBL7056594 | 0.78 | ALOX15 (0.62) | HSD17B10ALOX15ACE2 | |
| SCHEMBL3947375 | 0.78 | DRD2 (0.44) | HSD17B10GAA | |
| SCHEMBL31298039 | 0.76 | HSD17B10 (0.57) | HSD17B10ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1528925-B1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-04-22 | — | — | EP | claimed |
| US-7504408-B2 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | claimed |
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2005-11-10 | — | — | US | claimed |
| US-7504408-B2 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | disclosed |
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | TPD52L2, NQO2, CCNI | HSD17B10 4141/4885ALOX15 3710/4885GAA 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.